Treatment of Multiple Bone Metastases of Castration-Resistant Prostate Cancer With 225Ac-PSMA-617

Article Radiology, Nuclear Medicine & Medical Imaging

Hematologic toxicity profile and efficacy of [225Ac]Ac-PSMA-617 α-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer

Ismaheel O. Lawal et al.

Summary: The study demonstrates that [Ac-225]Ac-PSMA-617 therapy is effective in treating mCRPC patients with extensive skeletal metastases, with a low incidence of severe hematologic toxicity.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2022)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

First Clinical Results for PSMA-Targeted α-Therapy Using 225Ac-PSMA-I&T in Advanced-mCRPC Patients

Mathias Johannes Zacherl et al.

Summary: Our first clinical data for TAT using Ac-225-PSMA-I&T showed a promising antitumor effect in advanced metastatic castration-resistant prostate cancer, especially in patients previously treated with Lu-177-PSMA. These results are highly comparable to data on Ac-225-PSMA-617 TAT.

JOURNAL OF NUCLEAR MEDICINE (2021)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Ac-225-Prostate-Specific Membrane Antigen Therapy for Castration-Resistant Prostate Cancer A Single-Center Experience

Yasemin Sanli et al.

Summary: This retrospective study presented preliminary results of using Ac-225-PSMA therapy in patients with metastatic castration-resistant prostate cancer. Patients who had a PSA response after the first treatment cycle showed a potentially higher overall survival.

CLINICAL NUCLEAR MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

Michael S. Hofman et al.

Summary: [Lu-177]Lu-PSMA-617 showed a higher PSA response and fewer grade 3-4 adverse events compared to cabazitaxel in men with metastatic castration-resistant prostate cancer.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Oliver Sartor et al.

Summary: The radioligand therapy with Lu-177-PSMA-617 prolonged both imaging-based progression-free survival and overall survival in patients with PSMA-positive metastatic castration-resistant prostate cancer when added to standard care. Adverse events were more common with Lu-177-PSMA-617 but did not significantly impact quality of life.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging